Handok

Handok Diluted EPS

The Diluted Earnings per Share of Handok (002390.KS) as of Nov 17, 2026 is -156.43 KRW. In the previous year, Diluted Earnings per Share was -3,819.00 KRW — a change of -95.90% (higher).

Diluted EPS

-156.43KRW

YoY

-95.90%

Last updated:

Diluted Earnings per Share of Handok is 2025 -156.43 KRW. Diluted Earnings per Share of Handok was 2024 -3,819.00 KRW. It decreases by -95.90% higher compared to the previous year.

The Handok Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
586.71 KRW
Jan 1, 2019
2,537.78 KRW
Jan 1, 2020
1,958.78 KRW
Jan 1, 2021
239.39 KRW
Jan 1, 2022
776.22 KRW
Jan 1, 2023
-2,092.31 KRW
Jan 1, 2024
-3,819.00 KRW
Jan 1, 2025
-156.43 KRW
The Handok Diluted EPS history
YEARDiluted EPSYoY
-156.43KRW-95.90%
-3,819.00KRW+82.53%
-2,092.31KRW-369.55%
776.22KRW+224.25%
239.39KRW-87.78%
1,958.78KRW-22.82%
2,537.78KRW+332.54%
586.71KRW+50.01%
391.11KRW-175.43%
-518.48KRW+322.97%
-122.58KRW-214.52%
107.04KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Handok stock

Diluted Earnings per Share of Handok is -156.43 KRW in 2025.

Diluted Earnings per Share of Handok changed from -3,819.00 KRW to -156.43 KRW, representing a -95.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Handok since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Handok

All Key Metrics — Handok